Figure 7
From: Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
Pharmacokinetic profile of E5 subcutaneously administered to mice at different time points (n=3). The E5 concentration in circulating blood and main organs was measured with fluorescence imaging and quantified using FITC-conjugated E5. (a) The fluorescence intensity in the serum samples after FITC-E5 injection. (b) The fluorescence images of livers and kidneys at different time points. (c) The liver and kidney fluorescence intensity curve.
